Eli Lilly – Orna Therapeutics

WA-01087

Eli Lilly and Company (**Eli Lilly**) proposes to acquire 100% of the issued shares in Orna Therapeutics Holdings, LLC (**Orna Therapeutics**) pursuant to an Agreement and Plan of Merger. Eli Lilly is a US-based pharmaceutical company, which discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. Eli Lilly is headquartered in Indianapolis, US and is publicly listed on the New York Stock Exchange. Orna Therapeutics is a US-based pre-clinical biotechnology company developing a new class of engineered circular RNA (**oRNA**) therapeutics and immune tropic lipid nanoparticles (**LNP**) delivery technologies for the treatment of autoimmune disorders, and cancer conditions. Orna Therapeutics has a pipeline of pre-clinical in vivo Chimeric Antigen Receptor T-cell (**CAR-T**) therapies designed to treat B cell-driven autoimmune diseases.